Company / Financials
Bioventus Inc. Financials
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$568.1M
FY2025 · -0.9% YoY
Net Income
$22.7M
FY2025 · +162.9% YoY
Profit Margin
4.0%
FY2025 · net income / revenue
ROE
12.3%
FY2025 · return on equity
Total Assets
$683.6M
FY2025
Total Debt
$279.0M
1.52x debt/equity
Equity
$184.1M
FY2025
ROA
3.3%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.93 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$568.1M-0.9% YoYNet Income HistoryProfit after all expenses and taxes$22.7M+162.9% YoYGross Profit HistoryRevenue minus cost of goods sold$388.2M-0.0% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$179.9M-2.8% YoYOperating Income HistoryProfit from core business operations before interest and taxes$54.0M+455.2% YoYSG&A Expense HistorySelling, general, and administrative expenses$314.0M-8.7% YoYR&D Expense HistoryResearch and development spending$12.1M-13.2% YoYIncome Tax HistoryTotal income tax expense-$1.6M+70.4% YoYEPS (Basic) HistoryBasic earnings per share-$2.49+3.9% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$2.49+3.9% YoY